88IV - PR Newswire Asia's news - Biotechnology

< Previous page

| Title only | Print

Next page >

Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35 -ASC36_35FDC, a once-monthly subcutaneous (SQ) fixed dose combination (FDC) injection of ASC36 and ASC35, is a potentially first-in-class drug candidate which targets three validated targets of amylin ... 2026-08-10T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Dx&Vx Signs Two Material Transfer Agreements in Latin America Within Two Months -- "Technology Validated Across Both Public and Private Sectors" — Argentine biopharmaceutical company in July, South American public health institution in August sign consecutive KRNA material transfer agreements — Two of five cumulative MTAs now in Latin America, ... 2026-08-10T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer HONG KONG , Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) ... 2026-08-10T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
2026 Global Health Summit Opens in Hong Kong -- Global Healthcare Leaders Convene: Bringing Breakthroughs to Patients HONG KONG , Aug. 10, 2026 /PRNewswire/ -- The 2026 Global Health Summit ("GHS 2026"), jointly hosted by New Frontier Group ("New Frontier") and the Hong Kong Investment Corporation ... 2026-08-10T Biotechnology Computer/Electronics Health Care/Hospital Medical/Pharmaceuticals
Second PIC/S GMP Certification \| Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections SHANGHAI , Aug. 10, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces that its wholly-owned subsidiary ... 2026-08-10T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. ... 2026-08-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Telix to Host R&D Day in New York City on September 22, 2026 MELBOURNE, Australia and INDIANAPOLIS , Aug. 6, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will host a Research and Development ... 2026-08-06T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
NYSE Content Update: Expedition Therapeutics Secures $115 Million Series B NYSE issues a pre-market daily advisory direct from the trading floor. ... 2026-08-05T Banking/Financial Service Biotechnology Computer/Electronics
Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization CRANBURY, N.J. and SUZHOU,China , Aug. 5, 2026 /PRNewswire/ -- Recently, Porton Advanced Solutions Ltd. ("Porton Advanced") has officially been granted a Drug Manufacturing License (Class C) ... 2026-08-05T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Alteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme ™ -based hyaluronidase ALT-B4 Alteogen is eligible to receive up to US$365 million, including ... 2026-08-05T Biotechnology Health Care/Hospital

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved